MedTrace Logo

Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects

NCT02818699 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-12-10

No results posted yet for this study

Summary

The purpose of this clinical study is to determine the effect and safety of long-term intake of enzymatically modified isoquercitrin (EMIQ), a natural plant product on body fat loss in obese and overweight individuals.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks

DIETARY_SUPPLEMENT

EMIQ

280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks

Sponsors & Collaborators

  • Tufts University

    lead OTHER

Principal Investigators

  • Mohsen Meydani, DVM, PhD · USDA Human Nutrition Research Center on Aging

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-01
Primary Completion
2018-07-31
Completion
2018-09-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02818699 on ClinicalTrials.gov